The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
The deal between the White House and Democrats was earlier expected to raise the debt ceiling for two years and permanently end the sequester.Politicsread more
The deal could be announced as soon as next week, according to the report.Technologyread more
President Donald Trump held "constructive" discussions on a range of economic issues including trade and national security issues.Technologyread more
Secretary of Education Betsy DeVos and her family have seen their investments skyrocket since President Donald Trump started enacting pro-business policies. Meanwhile, DeVos...Politicsread more
See which stocks are posting big moves after the bell on July 22.Market Insiderread more
The construction industry is heavily dependent on Hispanic and Latino workers, a workforce that diminished during the last housing crisis and has not come close to full...Real Estateread more
Former NFL offensive lineman Jeff Hatch, who had previously been candid about his own struggles with opioid addiction and substance abuse, pleaded guilty Friday to a drug...Politicsread more
U.S. stock futures were indicating a higher Wall Street open and a possible reversal of recent negative trends.Morning Briefread more
A group of gold miners stocks, "BAANG," are better plays than mega-cap FAANG names, according to John Roque, technical analyst at Wolfe Research.Marketsread more
The hunt for yield has raised valuations for big pharma stocks above their biotech peers, a rare feat that presents a buying opportunity as growth prospects for biotech companies improve, according to Morgan Stanley.
"Recent revision trends and a focus on yield have propped up pharma, but faster sales growth, higher and expanding margins, and the potential for M&A should support biotech from these levels," wrote Adam Parker, chief U.S. equity strategist at Morgan Stanley.
For the first time in history, biotech and pharma companies trade at similar price-to-forward earnings, Parker notes, explaining that the discount in valuations is "too substantial" to dismiss.